Form 4: Alkermes Director Cato Laurencin Equity Transaction

Director Cato T. Laurencin acquired and exercised equity awards in Alkermes plc, resulting in a net increase in beneficial ownership.

Summary

• Director Cato T. Laurencin exercised 6,142 restricted stock units (RSUs) on May 21, 2026.
• 1,475 shares were withheld by the company to cover tax obligations at a price of $36.95 per share.
• The director was granted 11,538 non-qualified stock options and 5,409 new RSUs on May 20, 2026.
• Following these transactions, the director holds 33,769 ordinary shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting routine director equity compensation rather than a strategic shift.

Positives

• Director maintains a significant equity stake in the company, aligning interests with shareholders.
• The acquisition of new stock options and RSUs indicates continued long-term commitment to the company.

Negatives

• The transaction involved the withholding of shares for tax purposes, which is a standard but routine reduction in total potential holdings.

Risks

• Future value of equity awards is subject to market volatility and the company's share price performance.
• Vesting of new awards is contingent upon the passage of time or the next annual general meeting.

Future Outlook

The newly granted equity awards vest in full on the earlier of the one-year anniversary of the grant or the date of the next annual general meeting occurring at least 50 weeks after the grant.

Industry Context

StockSavvy.ai notes that this filing represents standard director compensation and equity management, which is common practice in the biopharmaceutical sector to ensure board alignment with long-term corporate performance.

Comparison to Industry Standards

• The use of RSUs and stock options as director compensation is consistent with standard corporate governance practices for mid-to-large cap pharmaceutical companies.
• Tax withholding upon RSU vesting is a standard administrative procedure across the industry.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity compensation event for a director.

Next Steps

• Vesting of the 11,538 stock options and 5,409 RSUs granted on May 20, 2026.

Key Dates

Keywords

Alkermes, ALKS, Form 4, Insider Trading, Equity Compensation, Director Ownership